Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric van der Helm

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Microbe|March 5, 2026
Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation studyAnders Østergaard Petersen, Birgitte Damholt, Mette Grove, et al.
Nature Biotechnology|May 4, 2023
Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in miceYilmaz Emre Gencay, Džiuginta Jasinskytė, Camille Robert, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Microbe|March 5, 2026
Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation studyAnders Østergaard Petersen, Birgitte Damholt, Mette Grove, et al.
Nature Biotechnology|May 4, 2023
Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in miceYilmaz Emre Gencay, Džiuginta Jasinskytė, Camille Robert, et al.
Pageof 2